Mesenchymal stem cells for multiple sclerosis: hype or hope?

Affiliations

¹ Institute of Clinical Neuroimmunology, University Hospital and Biomedical Centre, Faculty of Medicine, Ludwig Maximilians University Munich, Munich D-81377, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. Electronic address: reinhard.hohlfeld@med.uni-muenchen.de.

Comment

Reinhard Hohlfeld. Lancet Neurol. 2021 Nov.

. 2021 Nov;20(11):881-882.

doi: 10.1016/S1474-4422(21)00324-0.

¹ Institute of Clinical Neuroimmunology, University Hospital and Biomedical Centre, Faculty of Medicine, Ludwig Maximilians University Munich, Munich D-81377, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. Electronic address: reinhard.hohlfeld@med.uni-muenchen.de.

No abstract available

Conflict of interest statement

RH declares no competing interests.

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS; MESEMS investigators. Uccelli A, et al. Lancet Neurol. 2021 Nov;20(11):917-929. doi: 10.1016/S1474-4422(21)00301-X. Lancet Neurol. 2021. PMID: 34687636 Clinical Trial.